key: cord-0007260-cijfcn6b
authors: Aoki, Yoshitsugu; Nagata, Tetsuya; Yokota, Toshifumi; Nakamura, Akinori; Wood, Matthew J.A.; Partridge, Terence; Takeda, Shin'ichi
title: Highly efficient in vivo delivery of PMO into regenerating myotubes and rescue in laminin-α2 chain-null congenital muscular dystrophy mice
date: 2013-12-15
journal: Hum Mol Genet
DOI: 10.1093/hmg/ddt341
sha: c6a196e92bebd55ed2ef1989d350df9bce33f8e4
doc_id: 7260
cord_uid: cijfcn6b

Phosphorodiamidate morpholino oligomer (PMO)-mediated exon skipping is among the more promising approaches to the treatment of several neuromuscular disorders including Duchenne muscular dystrophy. The main weakness of this approach arises from the low efficiency and sporadic nature of the delivery of charge-neutral PMO into muscle fibers, the mechanism of which is unknown. In this study, to test our hypothesis that muscle fibers take up PMO more efficiently during myotube formation, we induced synchronous muscle regeneration by injection of cardiotoxin into the tibialis anterior muscle of Dmd exon 52-deficient mdx52 and wild-type mice. Interestingly, by in situ hybridization, we detected PMO mainly in embryonic myosin heavy chain-positive regenerating fibers. In addition, we showed that PMO or 2′-O-methyl phosphorothioate is taken up efficiently into C2C12 myotubes when transfected 24–72 h after the induction of differentiation but is poorly taken up into undifferentiated C2C12 myoblasts suggesting efficient uptake of PMO in the early stages of C2C12 myotube formation. Next, we tested the therapeutic potential of PMO for laminin-α2 chain-null dy(3K)/dy(3K) mice: a model of merosin-deficient congenital muscular dystrophy (MDC1A) with active muscle regeneration. We confirmed the recovery of laminin-α2 chain and slightly prolonged life span following skipping of the mutated exon 4 in dy(3K)/dy(3K) mice. These findings support the idea that PMO entry into fibers is dependent on a developmental stage in myogenesis rather than on dystrophinless muscle membranes and provide a platform for developing PMO-mediated therapies for a variety of muscular disorders, such as MDC1A, that involve active muscle regeneration.

Duchenne muscular dystrophy (DMD), the most common form of muscular dystrophy, involves progressive deterioration of muscle function. DMD is caused mainly by a frameshift deletion, nonsense or duplication mutations in the DMD gene, which encodes the protein dystrophin (1) . The milder Becker muscular dystrophy (BMD) typically results from in-frame deletions in the DMD gene that allows the expression of limited amounts of an internally truncated but functional protein (2) .

In recent years, RNA-targeted splice-correction therapy by antisense oligonucleotide (AO) in DMD muscle with the object of restoring an in-frame, Becker-like transcript is among the more promising therapeutic approaches to treating DMD (3, 4) . To this end, systemic administration of AO, such as phosphorodiamidate morpholino oligomers (PMOs), targeting specific exon(s) in the Dmd gene has been shown to restore the reading frame and induce body-wide production of partially functional BMD-like dystrophin in mouse and dog models of DMD (5) (6) (7) (8) . Currently, this method was shown to be promising and safe in phase II trials with PMO (9) or 2 ′ -O-methyl phosphorothioate (2 ′ OMePS), which is also the most common AO (10) , targeting exon 51 for DMD.

PMO, which has a neutral chemistry, provides outstanding safety characteristics and excellent in vivo efficacy and is suitable for human use. Moreover, PMO is being used extensively as a tool for selective inhibition of gene expression in cell culture models. However, the poor delivery of the PMO limits the application of PMO-mediated therapy for DMD or other muscular dystrophies. At present the precise mechanism of PMO entry into dystrophin-deficient muscle fibers is still unknown (11, 12) . A dominant hypothesis is that PMO enters dystrophin-deficient muscle fibers as a result of abnormal membrane permeability, a so-called 'leaky membrane' (13, 14) .

Here, we show that embryonic myosin heavy chain (eMHC) and dystrophin double-positive regenerating myotubes can incorporate PMO efficiently into Dmd exon 52-deficient mdx52 (15) and wild-type (WT) mice. Our in vitro studies of C2C12 myoblasts suggest that PMO or 2 ′ OMePS is taken up preferentially into muscle cells during the process of myotube formation. We also tested the therapeutic potential of PMO treatment on the dy 3K /dy 3K mouse (16) : a model of laminin-a2 chain (merosin)-deficient congenital muscular dystrophy (MDC1A) (MIM156225) with active muscle regeneration. Our results support the idea that PMO entry into muscle fibers is dependent on a developmental stage in myogenesis rather than on an intrinsic defect in the membrane of dystrophinless muscle fibers: the 'leaky-membrane' hypothesis. As such it provides a platform for developing PMO-mediated therapies for a variety of muscular disorders, such as MDC1A, that involve active muscle regeneration.

Induction of exon 51 skipping in dystrophin-deficient mdx52 but not in WT mice after systemic PMO injection, suggesting abnormally high membrane permeability in mdx52 mice

To examine the effect of systemic PMO-mediated exon 51 skipping (Supplementary Material, Fig. S1A ), we injected 5-week-old mdx52 and BL6 WT mice with a single dose of 51Do (Table 1) , which targets the splice donor site of exon 51 of the Dmd gene, at a range of doses 80, 160, 320 or 640 mg/ kg. Two weeks after the injection, the gastrocnemius muscles were isolated and analyzed by reverse transcription -polymerase chain reaction (RT -PCR). We could detect no skipped bands in WT mice but exon 51 skipping was induced in a highly dosedependent manner with the range of 80-640 mg/kg doses, showing approximately up to 90% skipping efficiency in mdx52 mice by RT -PCR (Supplementary Material, Fig. S1B ).

Enhancement of dystrophin expression after intramuscular injection of PMO into very actively regenerating TA muscles of mdx52 mice at 5 weeks of age

To investigate the mechanism of PMO uptake into muscle fibers, we first evaluated the percentage of centrally nucleated fibers, a marker of regenerated fibers, across a range of ages in mdx52 (n ¼ 3, each age group). Centrally nucleated fibers appeared around 3 weeks, dramatically increased around 4 -5 weeks and reached 80% after 16 weeks in mdx52 mice ( Fig. 1A and B) (Supplementary Material, Fig. S2 ). Next, we injected PMO 51Do (400 mg/kg body weight) into both tibialis anterior (TA) muscles of mdx52 mice aged 3 -32 weeks to induce exon 51 skipping ( Fig. 1C ) and evaluated the extent of dystrophin expression by immunohistochemistry. Two weeks after the injection, the TA muscles were isolated and analyzed by immunohistochemistry. The percentage of dystrophin-positive fibers was 45% on average when PMO was injected at 4 weeks and approximately 20% when PMO was injected from 6 to 32 weeks ( Fig. 1D and E). We found that the percentage of dystrophin-positive fibers was highest when PMO was injected into mdx52 mice at age 5 weeks when muscle regeneration was very active.

Classification of dystrophin-positive fibers into two types: Bromodeoxyuridine-positive small-caliber fibers and bromodeoxyuridine-negative normal-caliber fibers in mdx52 mice

To further investigate the phase of PMO uptake, we administered bromodeoxyuridine (BrdU) in the drinking water (0.8 mg/ml) for 6 days after a single intramuscular injection of PMO 51Do (400 mg/kg body weight) to label newly regenerated fibers. We injected into TA muscle of mdx52 mice aged 5 and 32 weeks. Mice were killed 2 weeks after the PMO injection and TA muscles were removed and analyzed by immunohistochemistry for dystrophin, BrdU and DAPI ( Fig. 2A) . We found that dystrophin-positive fibers could be classified into two types: BrdU-positive small-caliber fibers with diameters of 30-40 mm and BrdU-negative normal-caliber fibers with diameters of 40-60 mm at 5 and 32 weeks in mdx52 mice ( Fig. 2B and C) . The total numbers of dystrophin-positive fibers were significantly higher in the mice injected with PMO at 5 weeks than at 32 weeks Positive probe CAAACAGAAGGTATGGATAAAACAA Negative probe TTGTTTTATCCATACCTTCTGTTTG and the proportion that were of BrdU-positive, small-caliber fibers was also significantly greater (Fig. 2D) . Then, we injected PMO (320 mg/kg) into the tail vein of mdx52 mice at 5 weeks, which were administered of BrdU in the drinking water (0.8 mg/ml) for 6 days, and performed immunohistochemistry for dystrophin, BrdU and DAPI 2 weeks after the injection (Fig. 2E) (Fig. 2F) . These data suggest that immature regenerated fibers, which are called myotubes, could take up PMO more efficiently than mature fibers.

In this study, we evaluated the mechanism of PMO entry into small-caliber BrdU-positive fibers. To induce the synchronous regeneration of fibers, cardiotoxin (CTX) was injected intramuscularly into TA muscle of mdx52 mice at age 5 weeks (Supplementary Material, Fig. S3 ). At 1 -5 days after CTX injection, PMO (400 mg/kg body weight) targeting the splice donor site of exon 51 was injected into each TA muscle followed by oral administration of BrdU (0.8 mg/ml) for 7 days (Fig. 3A) . Two weeks later, TA muscles were obtained and analyzed by RT -PCR, immunohistochemistry and western blotting. The percentage of dystrophin-positive fibers by immunohistochemistry ( Fig. 3B and C) and dystrophin expression level by western blotting ( Fig. 3D and E) peaked in muscles where PMO had been injected at 4 days after CTX injection. On histology, the TA muscle BrdU and eMHC double-positive small-caliber fibers were seen at high levels at 4 days after CTX injection (Supplementary Material, Fig. S4 ). These results suggest that PMO was taken up very efficiently when eMHC-positive small-caliber fibers were mainly seen in mdx52 mice.

Dramatical induction of exon 51 skipping following systemic PMO injection at 4 days after CTX injection into TA muscles of WT mice

Then we examined the localization of PMO in muscle cryosections using fluorescein-conjugated PMO (f-PMO). First, f-PMO (400 mg/kg body weight) targeting the splice donor site of exon 51 was injected into each TA muscle of mdx52 mice at age 5 weeks. Two weeks later, TA muscles were obtained and analyzed by RT -PCR and immunohistochemistry. We found that both PMO and f-PMO could induce similarly efficient exon 51 skipping and dystrophin expression at the fiber membrane (Supplementary Material, Fig. S5A and B). We next investigated whether the f-PMO is taken up into eMHC-positive regenerated fibers after CTX injection into muscles of 5-week-old WT mice, followed, 4 days later, by injection of f-PMO (400 mg/kg body weight) targeting the splice donor site of exon 51 into each TA muscle (Fig. 4A) . Two hours later, the mice were killed and TA muscles were removed for microscopic analysis. Clearly, 4 days after CTX injection f-PMO had entered small-caliber-regenerated fibers of less than 35 mm, but not normal-caliber fibers with peripheral nuclei (Fig. 4B ). Next, PMO 51Do (320 mg/kg) targeting the splice donor site of exon 51 was injected into the tail vein of 5-week WT mice 4 days after injection of CTX into their TA muscles (Fig. 4C ). The mice were killed 2 weeks later and TA muscles were removed and analyzed by RT-PCR. The skipping ratios as evaluated by RT -PCR were 0.1, 0.3, 0.7, 15.3, 8.9 and 4.3% at Days 1, 2, 3, 4, 5 and 6 after the CTX injection, respectively ( Fig. 4D and E) . These data show that small-caliber-regenerated fibers can take up PMO efficiently in WT mice with a strong preference at Days 4 and 5, the period of maximum myotube formation.

We next analyzed the characteristics of eMHC-positive regenerated fibers induced by CTX injury (Fig. 5A ). Four days after CTX intramuscular injection into TA muscles of 5-week-old WT mice, PMO 51Do (320 mg/kg) was injected via the tail vein. One hour later, the mice were killed and the TA muscles were removed for analysis by in situ hybridization with digoxigenin -alkaline phosphatase probes. This revealed that PMO 51Do was mainly present in the nucleus and to a lesser extent in the cytosol of small-caliber (,35 mm)-regenerated fibers, but was barely detectable in normal-caliber fibers with peripheral nuclei ( Fig. 5B and C). Immunohistochemistry showed that fibers in which PMO 51Do was detected expressed dystrophin at the membrane ( Fig. 5D and E).

In vitro evaluation of the period of uptake of PMO and 2 ′ OMePS by mouse C2C12 myotubes

To examine the period of PMO uptake, we initially evaluated the expression level of dystrophin during C2C12 myoblasts differentiation and found the expression of dystrophin 24 h after the change of growth medium to differentiation medium by RT -PCR (Fig. 6A) . Then, we transduced C2C12 myotubes with 10 mM PMO 51Do at 24, 48, 168 or 336 h after the medium change. We also tested the uptake period of 1 mM 2 ′ OMePS, which is one of the commonly investigated oligonucleotides chemistries used for targeting the intraexonic site of exon 51. Undifferentiated C2C12 myoblasts after 10 mM PMO or 1 mM 2 ′ OMePS were used as controls. After 48 h of incubation with PMO or 2 ′ OMePS, the cells were collected and analyzed by RT -PCR ( Fig. 6B and C) . The skipping ratios of C2C12 myotubes after 10 mM PMO transfection were 32.6, 22.7, 9.8 and 6.1% after 24, 48, 168 or 336 h following the medium change, respectively (Fig. 6D) . The skipping ratios after 1 mM 2 ′ OMePS transfection over the same set of time periods were 22.9, 13.1, 2.5 or 1.2% after 24, 48, 168 or 336 h after the medium change, respectively (Fig. 6E) . On the other hand, the skipping ratios of undifferentiated C2C12 myoblasts after 10 mM PMO or 1 mM 2 ′ OMePS were 6.1 or 1.7%, respectively ( Fig. 6D and E) . These data support the idea that PMO or 2 ′ OMePS is most efficiently taken up into muscle cells in the early stages of C2C12 myotube formation.

Proof of efficient PMO uptake by severely affected myofibers in dy 3K /dy 3K mice following systemic PMO injection

Finally, we performed PMO-mediated exon skipping for dy 3K /dy 3K mice, which are an animal model of laminin-a2 chaindeficient congenital muscular dystrophy and show severe dystrophic change with active muscle regeneration. Skipping exon 4 of the murine Lama2 gene in dy 3K /dy 3K mice corrects the open reading frame and could lead to the production of a truncated laminin-a2 chain (Fig. 7A) . We first identified effective AO sequences in dy 3k /dy 3k fibroblasts. We designed seven AO sequences targeting either exonic sequences or exon-intron junctions of the murine Lama2 exon 4 ( Fig. 7B ; sequences in Table 3 ). We then transfected one or two of the seven AOs (10 mM in total) into dy 3k /dy 3k fibroblasts (17) . After 48 h incubation, we analyzed RNA fractions by RT -PCR using the primers described in Supplementary Material, Figure S6 . Among the AOs examined, PMO 4B plus 4D were shown to be capable of inducing exon 4 skipping at a level approaching 80%, the highest among the combinations that we examined by RT -PCR ( Fig. 7C and D) . 4B and 4D were designed to target the exonic sites of exon 4. We therefore injected the combination of two AOs (400 mg/kg body weight) into the TA muscles of dy 3K /dy 3K mice at age 10 days. Fifteen days later, TA muscles were obtained and analyzed by RT -PCR and immunohistochemistry. We found by RT -PCR that 4B plus 4D could induce exon 4 skipping (Fig. 8A) . We confirmed correct exon 4 skipping by direct sequencing of the RT -PCR products (Fig. 8B) . Moreover, up to 20% of fiber membranes were laminin-a2 positive by immunohistochemistry (Fig. 8C ). After intraperitoneal injection (150 mg/kg in total) of the 2-PMO combination into dy 3K /dy 3K mice at postnatal at age 10 days, we found that 4B plus 4D could induce exon 4 skipping by RT-PCR (Fig. 8D ). Our study results showed a trend toward improvement in life span of PMO-treated dy 3k /dy 3k mice compared with saline-treated dy 3K /dy 3K mice (Fig. 8E) . These data suggest the potential of PMO-mediated therapy targeting myotubes for MDC1A.

We demonstrated here that PMO can be taken up into dystrophin and eMHC-positive regenerated fibers in WT mice. We also showed that PMO and 2 ′ OMePS could be taken up into C2C12 myoblasts in the early stages of C2C12 myotube formation. These results suggest that we can apply PMO-or 2 ′ OMePSmediated therapy targeting myotube formation to other muscular diseases. To confirm our hypothesis, we finally showed the restoration of laminin-a2 chain expression by exon 4 skipping against the Lama2 gene and a prolonged lifespan after intraperitoneal injection of PMO into dy 3K /dy 3K mice, which is a model of MDC1A (16) . PMO, which has a neutral chemistry, provides greatly decreasing the chance of catastrophic off-target antisense effects, and minimizes interactions with cationic moieties of proteins (11, (18) (19) (20) (21) . These characteristics of PMO contribute to their extremely low toxicity and suitability for use in human. PMO is also being used extensively as a tool for selective inhibition of gene expression in cell culture models (22) .

At present, the changes of membrane permeability of dystrophin-deficient muscle membrane, so-called 'leaky membrane hypothesis', facilitating a route of entry for the PMO into myofibers, are a favored explanation for PMO uptake (23 -25) . This hypothesis is based on the clinical evidence that dystrophin-deficient muscle fibers are prone to be injured by contraction and that the injury causes leakage of soluble cytoplasmic proteins such as creatine kinase (26, 27) . In addition, it is reported that intravenously delivered PMO shows very poor delivery to normal muscle, while dystrophin-deficient muscle or intramuscular injection in normal muscle shows good delivery (28) . Further, Evans blue, a low molecular-weight diazo dye which has a very high affinity for serum albumin, does not cross into skeletal muscle fibers in normal mice but mdx mice, a dystrophin-deficient animal model for DMD, show significant Evans blue accumulation in skeletal muscle fibers (29, 30) .

However, the hydrophobic plasma membrane constitutes an almost insurmountable barrier around muscle fibers, resulting in poor delivery of the neutral PMO, and preventing optimization of PMO-mediated therapy for DMD or other muscular dystrophies (31, 32) . To overcome this delivery issue with PMO, recent developments using cell-penetrating peptide-conjugated PMO, where a short cationic peptides that penetrate cells by interacting with the negatively charged plasma membrane, may become an effective strategy for reducing both dose levels and administration frequencies (33 -36) . But we still face issues of off-target effects or high toxicity in humans because of the nonspecific delivery-facilitated properties and the facilitated interactions with other proteins (37) (38) (39) (40) . Therefore, it is important to understand the detailed mechanisms of PMO entry into muscle fibers to improve the poor delivery of PMO and optimize it as a therapeutic intervention for DMD or other muscular diseases.

In this study, we found that exon 51 skipping was induced dose dependently in mdx52 mice but that no skipping was induced in WT mice after systemic injection of PMO (640 mg/kg). This finding conforms the 'leaky membrane hypothesis'. However, PMO was most efficiently taken up into eMHC-positive regenerating fibers at 4 days following CTX injection into TA muscles, which express dystrophin at the muscle plasma membrane in WT mice. The degeneration-regeneration process induced by CTX injection was well documented as follows: after CTX injection, satellite cell proliferation occurs within 2 days, myogenic differentiation is initiated within 3 days, new myotube formation is evident within 5 days and muscle architecture is largely restored within 10 days (41) . Taken together, our in vivo study by CTX injection suggests PMO uptake is more prominent during stages from myogenic differentiation to myotube formation than cell proliferation stage. We also showed that PMO and 2 ′ OMePS is taken up efficiently in the early stages of C2C12 myotube formation. These data suggest that the uptake mechanism is not simply attributable to a change in membrane permeability but also involves an unknown mechanism in the early stages of C2C12 myotube formation. It is reported that PMO internalization in uptake-permissive cells is specific, saturable and energy dependent, suggesting a receptor-mediated mechanism (22) . These data suggest that immature regenerated fibers, which are called myotubes, could take up PMO more efficiently than mature fibers. In consequence, we confirmed that there is already a leaky gateway into dystrophin-deficient muscle fibers. But more importantly, these findings provide a conceptual advance in that it supports the idea that PMO entry into muscle fibers is dependent on a developmental stage in myogenesis rather than on an intrinsic defect in the dystrophin-deficient muscle membrane: the 'leaky-membrane' hypothesis. As such it provides a platform for developing PMO-mediated therapies for a variety of muscular disorders, such as MDC1A, that involve active muscle regeneration.

To test the potential of PMO treatment targeting myotube formation, we used the dy 3K /dy 3K mouse which is a model of MDC1A. The dy 3K /dy 3K mice, with a pMC1neo polyA+ cassette in exon 4 of the Lama2 gene, are a null mutant for the laminin-a2 chain which is a major component of basal lamina in skeletal muscle and the peripheral nervous system (16) . In man, the laminin-a2 chain consists of six domains (I-VI) and exon 4 of the LAMA2 gene encodes a part of domain VI, which are predicted to form N-terminal globular (LN) structures (Supplementary Material, Fig. S7A ) (42) . The LN structures are essential for laminin aggregation into supramolecular networks and consequently for incorporation into basement membranes, thus mutations in this structures reduce the capacity of polymer formation (43) . Another merosin-deficient mouse, the dy 2J /dy 2J mouse, harbors a mutation in the LN structures which leads only to slightly reduced expression of a laminin-a2 chain partially lacking these structures and thus displays a relatively mild muscular dystrophy and peripheral neuropathy (44) . Therefore, we hypothesized that PMO-mediated exon 4 skipping could act to rescue dy 3K /dy 3K mice. In this study, we successfully confirmed the recovery of laminin-a2 chain by skipping of the mutated exon 4. Our data suggest that PMO, which was taken up into muscle fibers, may induce exon 4 skipping in dy 3K / dy 3K mice. More importantly, PMO-mediated exon 4 skipping has a real potential to become an effective therapy for MDC1A, since two nonsense mutations in exon 4 such as 547G . ANN166X and 677C . T/210X can cause MDC1A (45) . Furthermore, half of the patients with congenital muscular dystrophy in European populations have mutations of the LAMA2 gene (42), our data could offer a hope to patients struggling with the disease.

In conclusion, PMO or 2 ′ OMePS is taken up preferentially into mouse muscle cells during myotube fusion. Our results can provide a platform for developing PMO-mediated therapies for a variety of muscular disorders, such as MDC1A, that involve active muscle regeneration. They also directs us to interrogate myogenic developmental mechanisms as opposed to defects in membrane function in mature muscle fibers for clues as to how to facilitate PMO delivery in other myopathies.

Exon 52-deficient, X chromosome-linked muscular dystrophy (mdx52) mice were produced by a gene-targeting strategy and maintained at our facility (15) . The mice have been backcrossed to the C57BL/6J WT strain for more than eight generations. Male mdx52 mice ages 3 -32 weeks and WT mice age 5 weeks were used in this study. Heterozygous Lama2 gene-targeted dy 3K mice, which have a pMC1neo polyA+ cassette in exon 4 of the Lama2 gene, were maintained in our animal facility. The heterozygous mice were interbred to obtain homozygous dy 3K /dy 3K mice. Genotyping of the Lama2 deficiency was performed by PCR on tail genomic DNA. The PCR primers for the WT Lama2 allele and the mutant allele are described in Table 4 . Mice showing WT Lama2-negative and neo-positive PCR products were defined as Lama2 homodeficient (dy 3k /dy 3k ).

All experimental protocols in this study were approved by the Experimental Animal Care and Use Committee of the National Institute of Neuroscience, National Center of Neurology and Psychiatry, Japan.

BrdU (Sigma-Aldrich, St. Louis, MO, USA) was dissolved in PBS (Gibco, Paisley, UK) and stored at 3 mg/ml at 2208C. Mice were treated with 0.8 mg/ml BrdU in their drinking water for 7 days. BrdU solution was prepared in sterile water, protected from light exposure and changed daily.

AO for targeted skipping of exon 51 during dystrophin pre-mRNA splicing in mice were designed to anneal to the 3 ′ splice site (51Do) according to our previously published report (5) . The sequence was synthesized using a PMO, f-PMO (Gene Tools, LLC, Philomath, OR, USA) or 2 ′ OMePS (Operon Biotechnologies, Tokyo, Japan). Primers for RT-PCR and sequencing analysis were synthesized by Operon Biotechnologies and are listed in Table 4 .

For local studies, PMO or 2 ′ OMePS at a dose of 400 mg/kg body weight was injected into each TA muscle of mdx52 mice. Muscles were obtained 2 weeks after the intramuscular injection and analyzed by RT -PCR and the cryosections by immunohistochemistry. For the systemic studies, a dose of 80-640 mg/kg PMO in 100 ml of saline or 100 ml saline was injected into the tail vein of mdx52 mice or WT mice, singly, and mice were examined 2 weeks after the injection. Muscles were dissected immediately, snap-frozen in liquid nitrogen-cooled isopentane and stored at 2808C for RT -PCR, immunohistochemistry and western blotting.

In the 2% differentiation medium, C2C12 myotubes were incubated up to 14 days. We then transfected PMO or 2 ′ OMePS at the final concentration of 10 or 1 mM, respectively, into C2C12 myotubes without any transfection agents and incubated them for 48 h.

Total RNA was extracted from cells or frozen tissue sections using TRIzol (Invitrogen, Carlsbad, CA, USA). Two hundred nanograms of total RNA template were used for RT-PCR with a QuantiTect Reverse Transcription Kit (Qiagen, Crawley, UK) according to the manufacturer's instructions. The cDNA product (0.5 ml) was then used as the template for PCR in a 20-ml reaction with 0.1 units of TaqDNA polymerase (Qiagen). The reaction mixture comprised 10× PCR buffer (Roche, Basel, Switzerland), 10 mM of each dNTP (Qiagen) and 10 mM of each primer. The primer sequences were Ex50F 5 ′ -TTTACTTCGGGAGCTGAGGA-3 ′ and Ex53R 5 ′ -ACCTG TTCGGCTTCTTCCTT-3 ′ for amplification of cDNA from exons 50 to 53. The cycling conditions were 958C for 4 min, then 35 cycles of 948C for 0.5 min, 608C for 0.5 min, 728C for 0.5 min and finally 728C for 7 min. The intensity of PCR bands was analyzed using ImageJ software (http://rsbweb.nih.gov/ij/), and skipping efficiency was calculated by using the following formula: [(the intensity of skipped band)/(the intensity of skipped band + the intensity of unskipped band)]. After the resulting PCR bands were extracted using a gel extraction kit (Qiagen), direct sequencing of PCR products was performed by the Biomatrix Laboratory Co., Ltd. (Chiba, Japan).

At least ten 8-mm cryosections were cut from flash-frozen muscles at 100-mm intervals. The serial sections were stained with polyclonal rabbit antibody P7 against the dystrophin rod domain (a gift from Dr. Qi-Long Lu, Carolinas Medical Center, Charlotte, NC, USA), monoclonal mouse antibody developmental MHC (Leica Biosystems, Newcastle Upon Tyne, UK), anti-laminin-a2 monoclonal rat antibody 4H8-2 (Abcam, Cambridge, UK) and anti-laminin polyclonal rabbit antibody L9393 (Sigma-Aldrich). Alexa-488 or 568 (Molecular Probes, Cambridge, UK) was used as a secondary antibody. DAPI containing a mounting agent (Vectashield; Vector Laboratories, Burlingame, CA, USA) was used for nuclear counterstaining. The maximum number of dystrophin-positive fibers in one section was counted, and the TA muscle fiber sizes were evaluated using a BZ-9000 fluorescence microscope (Keyence, Osaka, Japan). Hematoxylin and eosin staining was performed using Harris hematoxylin and eosin.

Muscle protein from cryosections was extracted with lysis buffer as described previously (5) . A total of 2 -20 mg protein was loaded onto a 5-15% XV Pantera Gel (DRC, Tokyo, Japan). The samples were transferred onto an Immobilon polyvinylidene fluoride membrane (Millipore, Billerica, MA, USA) by semi-dry blotting at 5 mA/mm 2 for 1.5 h. The membrane was incubated with the C-terminal monoclonal antibody Dys2 (Leica Biosystems, Newcastle Ltd.) at room temperature for 1 h. The bound primary antibody was detected by horseradish Table 3 . AO sequences against exon 4 of the Lama2 gene of mice used in this study

Position Sequence

+171+195 GACCTCATCATCTTTGGCGTAGGAT peroxidase-conjugated goat anti-mouse IgG (Cedarlane, Burlington, ON, USA) and SuperSignal chemiluminescent substrate (Pierce, Rockford, IL, USA). Anti-b-actin antibody was used as a loading control. The signal intensity of detected bands of the blots was quantified using ImageJ software and normalized to the loading control.

In situ hybridization DNA probes with 3 ′ -DIG tailing for in situ hybridization were synthesized by Nihon Gene Research Laboratories Inc.

(Sendai, Japan) and are listed in Table 2 . At least ten 10-mm cryosections were cut from flash-frozen muscles. The sections were 

Statistical differences were assessed by one-way analysis of variance with differences among the groups assessed by a Tukey's comparison or Fisher's exact test. All data are reported as mean values + SD or SEM. The level of significance was set at P , 0.05.

Dystrophin: the protein product of the Duchenne muscular dystrophy locus

An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus

Exon skipping during splicing of dystrophin mRNA precursor due to an intraexon deletion in the dystrophin gene of Duchenne muscular dystrophy Kobe

Toward an oligonucleotide therapy for Duchenne muscular dystrophy: a complex development challenge

In-frame dystrophin following exon 51-skipping improves muscle pathology and function in the exon 52-deficient mdx mouse

Bodywide s kipping of exons 45-55 in dystrophic mdx52 mice by systemic antisense delivery

Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs

Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles

Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study

Systemic administration of PRO051 in Duchenne's muscular dystrophy

Neutrally charged phosphorodiamidate morpholino antisense oligomers: uptake, efficacy and pharmacokinetics

Intracellular delivery strategies for antisense phosphorodiamidate morpholino oligomers

Dystrophin protects the sarcolemma from stresses developed during muscle contraction

Time course of changes in plasma membrane permeability in the dystrophin-deficient mdx mouse

Primer pair for the Lama2 gene Forward primer: 5 ′ -GGTGGCAGAGTCCCAGTATC-3 ′ Reverse primer: 5 ′ -CGATTTCTCTGGGGTCTTTG-3 ′ (iii) Primer pair for the WT Lama2 allele Forward primer: 5 ′ -CCAGATTGCCTACGTAATTG-3 ′ Reverse primer: 5 ′ -CCTCTCCATTTTCTAAAG-3 ′ (iv) Primer pair for the mutant

Targeted disruption of exon 52 in the mouse dystrophin gene induced muscle degeneration similar to that observed in Duchenne muscular dystrophy

Laminin alpha2 chain-null mutant mice by targeted disruption of the Lama2 gene: a new model of merosin (laminin 2)-deficient congenital muscular dystrophy

Antisense PMO found in dystrophic dog model was effective in cells from Exon 7-deleted DMD patient

Pharmacokinetics and biodistribution of phosphorodiamidate morpholino antisense oligomers

Resistance of morpholino phosphorodiamidate oligomers to enzymatic degradation

Morpholinos and their peptide conjugates: therapeutic promise and challenge for Duchenne muscular dystrophy

Optimizing antisense oligonucleotides using phosphorodiamidate morpholino oligomers

Cellular uptake of neutral phosphorodiamidate morpholino oligomers

Duchenne dystrophy: electron microscopic findings pointing to a basic or early abnormality in the plasma membrane of the muscle fiber

A renaissance for antisense oligonucleotide drugs in neurology: exon skipping breaks new ground

Restoring dystrophin expression in Duchenne muscular dystrophy muscle progress in exon skipping and stop codon read through

Activity, creatine kinase, and myoglobin in Duchenne muscular dystrophy: a clue to etiology?

Our trails and trials in the subsarcolemmal cytoskeleton network and muscular dystrophy researches in the dystrophin era

Preclinical PK and PD studies on

′ -O-methyl-phosphorothioate RNA antisense oligonucleotides in the mdx mouse model

Visualization of dystrophic muscle fibers in mdx mouse by vital staining with Evans blue: evidence of apoptosis in dystrophin-deficient muscle

Animal models for muscular dystrophy show different patterns of sarcolemmal disruption

RNA-targeted splice-correction therapy for neuromuscular disease

Exon-skipping therapy for Duchenne muscular dystrophy

Extensive and prolonged restoration of dystrophin expression with vivo-morpholino-mediated multiple exon skipping in dystrophic dogs

Scavenger receptor-mediated uptake of cell-penetrating peptide nanocomplexes with oligonucleotides

Cell-penetrating peptide-morpholino conjugates alter pre-mRNA splicing of DMD (Duchenne muscular dystrophy) and inhibit murine coronavirus replication in vivo

Functional rescue of dystrophin-deficient mdx mice by a chimeric peptide-PMO

Cellular uptake of antisense morpholino oligomers conjugated to arginine-rich peptides

Pharmacokinetics, biodistribution, stability and toxicity of a cell-penetrating peptide-morpholino oligomer conjugate

Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: potential mechanism of action

Phosphorothioate oligonucleotides inhibit the intrinsic tenase complex

Myogenic satellite cells: physiology to molecular biology

Merosin and congenital muscular dystrophy

Skeletal muscle laminin and MDC1A: pathogenesis and treatment strategies

Identification of a novel mutant transcript of laminin alpha 2 chain gene responsible for muscular dystrophy and dysmyelination in dy2J mice

Merosin-deficient congenital muscular dystrophy, autosomal recessive (MDC1A, MIM#156225, LAMA2 gene coding for alpha2 chain of laminin)

ESEfinder: A web resource to identify exonic splicing enhancers

The authors thank Yuko Suzuki and Michihiro Imamura for insightful discussions about this study. We thank Takashi Saito, Jun Tanihata, Yuko-Motohashi Shimizu, Satoru Masuda, Hayashiji Nozomi and Ryoko Nakagawa for useful discussions and technical assistance. We also thank Kenji Kuwabara, Kazushi Takagaki, Satoru Sonoke, Kaoru Fujiwara and other members of Nippon Shinyaku Co Ltd. 

Supplementary Material is available at HMG online.